# The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

> **NCT02251847** · PHASE3 · UNKNOWN · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 400 (estimated)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Rosuvastatin/Ezetimibe

## Key facts

- **NCT ID:** NCT02251847
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2014-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251847, "The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02251847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*